Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar

Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, von Büdingen HC, Kou X, Weber K, Greenberg B. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022 Jul 5;66:104025. doi: 10.1016/j.msard.2022.104025. Epub ahead of print. PMID: 36007339.

All clinical trials, All demyelinating disease (CNS), Autoimmune diseases, Devic's syndrome, Neuromyelitis optica spectrum disorder, Patient safety,


Related Posts